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INTRODUCTION
• Metyrapone blocks cortisol production by inhibiting 11β-hydroxylation of 11-deoxycortisol, the last step of 
cortisol synthesis (Figure 1).1
• Based on observational retrospective studies published over more than 50 years, metyrapone is approved 
for the treatment of endogenous Cushing’s syndrome (CS) in 15 European countries.2 
• PROMPT is the first prospective study to document the safety and efficacy of metyrapone using modern 
assay techniques.
Figure 1: Mode of action of metyrapone
Adapted from: Kulstad EB, et al. West J Emerg Med. 2010;11(2):161–172. Creative Commons (CC BY-NC 4.0)
METHODS
Patients
• Adult patients with a new diagnosis of endogenous CS of any etiology (except advanced adrenal carcinoma) 
or recurrent or persistent Cushing’s disease (CD) after transsphenoidal surgery (TSS), were eligible if three 
baseline urinary free cortisol (UFC) values measured over 24 hours were at least 50% above the upper limit of 
normal (ULN=165 nmol/24h). 
Study design (Figure 2)
• The international European Phase III/IV PROMPT study commenced in 2015 (ClinicalTrial.gov registry: 
NCT02297945). 
• This single arm, open-label, multicenter trial is ongoing in seven countries:
 –  Belgium,     Germany,     Hungary,     Italy,     Poland,     Spain,   Turkey
Figure 2: Study design
MTP: metyrapone; UFC: urinary free cortisol; ULN: upper limit of normal
• Metyrapone given three or four times daily was individually titrated based on cortisol levels in urine and serum 
over 12 weeks to achieve normal urine and serum cortisol levels according to a titration scheme (Figure 2).
• After 12 weeks, patients whose mean value of 3 UFCs (mUFC) was less than twice the ULN, continued to 
receive metyrapone for another 24 weeks (Figure 2).
• Cortisol was measured in a central laboratory by liquid chromatography tandem–mass spectrometry (LC-MS/MS) 
method. This assay is used to avoid cross-reactivity of 11-deoxycortisol in cortisol immunoassays.
Table 1: Metyrapone titration scheme
Baseline UFC Initial MTP 
dose
MTP dose change










UFC ≤ ULN  
(165 nmol/24h) 
Or 
193 nmol/L ≤serum 
cortisol ≤330 nmol/L
Moderate CS 
Baseline UFC  
≤ 5 x ULN
750 mg/day ↑250–500 mg/day ↑250–500 mg/day Optimal dose reached
Severe CS 
Baseline UFC  
> 5 x ULN
1500 mg/day ↑500–1000 mg/day ↑500–1000 mg/day Optimal dose reached
CS: Cushing’s syndrome; MTP: metyrapone; UFC: urinary free cortisol; ULN: upper limit of normal
ENDPOINTS
•  The primary endpoint is to assess the efficacy of metyrapone to normalize mUFC after 12 weeks of treatment.
•  Secondary endpoints are: 
 –  Assessment of the efficacy of metyrapone to normalize serum and salivary cortisol after 12 weeks and 
UFC after 24 weeks;
 –  Assessment of changes in clinical symptoms of CS, systolic and diastolic blood pressure, and quality of 
life (CushingQoL and Tübingen CD QoL inventory);
 –  Assessment of safety and tolerability, including adverse events (AEs) and Ferriman-Gallwey score of 
hirsutism in women;
 – Assessment of impact of metyrapone blockade on circulating lipids, glucose, adrenocorticotropic 
hormone (ACTH), 11-deoxycortisol, deoxycorticosterone, renin/renin activity, androstenedione, 
dehydroepiandrosterone sulfate and total testosterone levels;
 – Estimation of time to 50% reduction of UFC, eucortisolemia, clinical and biochemical improvements. 
•  Exploratory endpoints include factors predicting success and response relationships.
Figure 3: Mean mUFC at baseline and at Week 12 in the initial 28 patients
mUFC: mean urinary free cortisol
STATUS
• The study commenced in 2015 and is ongoing.
• By April 2018, 35 patients were included: 24 women and 11 men, with a mean age of 45 years old (range: 21–73).
• A total of 32 patients had CD and 21 patients had previously undergone TSS (range: 1–3).
• Nine patients discontinued the study at/or after the primary objective endpoint (Week 12) owing to: 
inefficacy (n=3), mUFC >2 x ULN despite improvement by 70% (n=1), hirsutism (n=1), serious AEs (n=1; severe 
hypotension, cellulitis, venous thrombosis and renal insufficiency) and decision to undergo TSS despite 
control with metyrapone (n=3).
• The mean of the mUFC values in the first 28 patients treated over 12 weeks decreased from 860 nmol/24h 
at baseline to 186 nmol/24h at Week 12 (Figure 3).
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